I randomiserede, placebokontrollerede kliniske forsøg øgede filgrastim ikke forekomsten af bivirkninger forbundet med cytotoksisk kemoterapi.
In randomised, placebo-controlled clinical studies, filgrastim did not increase the incidence of undesirable effects associated with cytotoxic chemotherapy.